John Carroll wins the European Mediscience 'Commentator of the Year' award

I am pleased to announce FierceBiotech's own Editor-in-Chief John Carroll has won the award for "Commentator of the Year" from the European Mediscience Awards in London on June 19, 2014. 

The Commentator of the Year can be awarded to an analyst, a journalist, a columnist, a research house, a specialist website or a team that is dedicated to providing sharp, perceptive and penetrating commentary about the sector. Finalists this year included the BioCentury team, the Scrip Intelligence team and Matthew Goodman from The Sunday Times.

"I'd like to thank the judges as well as Sue Charles and all of the people at Instinctif, which sponsored this award," says Carroll. "Just being nominated alongside Matthew Goodman at The Sunday Times as well as the teams at BioCentury and Scrip was a great recognition of the work FierceBiotech has been doing in terms of expanding our coverage of the life sciences industry around the globe. Winning was a real honor and a great encouragement to us all."

John Carroll has been FierceBiotech's lead editor since 2003, shortly after the online publication was launched. He has been instrumental in building and defining our editorial strategy to include global coverage and expert analysis of the biotech industry. Recently he expanded FierceBiotech's coverage with the EuroBiotech Report, written by Nick Taylor, our weekly column covering the European biotech industry.

Mastering the art of communication is vital in this industry. John has a deep understanding of the biotech sector and is always one step ahead of his competition with breaking news, high level interviews and expert analysis. He exemplifies a great commentator and I am very happy that he is being recognized for his talents and achievements. We at FierceBiotech know what a great talent he is and I am very pleased to see his talents recognized by the industry.

Congratulations, John. This is a well-deserved achievement. -- Rebecca Friend (email | Twitter)

See the release from Instinctif Partners

Suggested Articles

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.